Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.30 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16968748 | 0.90 | — | — | |
| SCHEMBL10074589 | 0.86 | ALOX5 (0.39) | — | |
| SCHEMBL10075151 | 0.85 | KDM4E (0.42) | EGFR | |
| SCHEMBL10074890 | 0.84 | SMN1; SMN2 (0.37) | PIM1 | |
| SCHEMBL20514733 | 0.84 | SELL (0.39) | PIM1 | |
| SCHEMBL10074597 | 0.83 | GSK3B (0.50) | EGFRGSK3B | |
| SCHEMBL10074406 | 0.79 | NPC1 (0.46) | — | |
| SCHEMBL16968741 | 0.77 | MEN1 (0.34) | — | |
| SCHEMBL10074409 | 0.75 | KDM4E (0.40) | EGFR | |
| SCHEMBL10075134 | 0.73 | KDM4E (0.41) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9351971-B2 | Substituted 2,2′-biphenazines for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | claimed |
| US-9351971-B2 | Substituted 2,2′-biphenazines for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351971-B2 | Substituted 2,2′-biphenazines for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351971-B2 | Substituted 2,2′-biphenazines for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150216862-A1 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS THERAPEUTICS, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150216862-A1 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS THERAPEUTICS, INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150216862-A1 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS THERAPEUTICS, INC. | 2015-08-06 | — | — | US | disclosed |
| US-8987271-B2 | 2,2′-biphenazine compounds and methods useful for treating disease | EUTROPICS PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987271-B2 | 2,2′-biphenazine compounds and methods useful for treating disease | EUTROPICS PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8987271-B2 | 2,2′-biphenazine compounds and methods useful for treating disease | EUTROPICS PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20120225851-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225851-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225851-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012088438-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225851-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | MCL1, BCL3, BCL9 | EGFR 2978/4885PIM1 1386/4885GSK3B 2421/4885 |
| US-20150216862-A1 | 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES | MCL1, BCL3, BCL2L1 | EGFR 2699/4885PIM1 788/4885GSK3B 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.